Source: GlobeNewswire Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera Inc., USA (“Biofrontera”), a wholly owned subsidiary of Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today entered into an agreement to acquire all shares in Cutanea Life Sciences, Inc., USA (“Cutanea”) through its subsidiary Biofrontera Newderm LLC as…...

Source: FierceBiotech Stryker has acquired OrthoSpace, developers of a therapy for severely torn rotator cuffs, in a deal worth up to $220 million, split evenly between upfront cash and future milestone payments. The Israel-based OrthoSpace has developed a biodegradable balloon spacer that fits between the shoulder’s scapula and acromonion bones,…...

Source: PR Newswire PRINCETON, N.J., Feb. 27, 2019 /PRNewswire/ -- Sun Pharmaceutical Industries Inc., USA (SPII) today announced that it plans to present 19 abstracts featuring data on ILUMYA™ (tildrakizumab-asmn), a prescription medicine used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic or phototherapy, at the 77th Annual Meeting of the American Academy…...

Source: FierceBiotech Medtronic has received approval of an expanded indication from the FDA for its Pipeline Flex embolization device, for patients with smaller aneurysms found deeper in the brain. The system was previously approved for endovascular treatment with large or giant, wide-necked intracranial aneurysms, located in the internal carotid artery…...

Source: FierceHealthcare Anthem is planning to begin moving members into its new PBM, IngenioRx, in the second quarter of 2019, bumping up the projected launch from 2020. Anthem announced the change as part of its fourth-quarter earnings (PDF), saying it moved up IngenioRx’s launch because Cigna closed its acquisition of Anthem’s current pharmacy benefit manager,…...

Source: Sienna Biopharmaceuticals WESTLAKE VILLAGE, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced top-line results from a Phase 2b study of SNA-120 (pegcantratinib), the Company’s lead drug candidate developed using its proprietary Topical by Design™ platform. This Phase 2b study, in mild-to-moderate…...

Source: FierceBiotech 98point6, a digital health company that makes primary care doctors available to patients over cellphone messages, raised $50 million in a new financing round led by Goldman Sachs. Its platform uses artificial intelligence to automate the tasks that don’t require direct physician interaction, such as gathering information on…...

Source: FiercePharma As the FDA gets set to decide whether Sanofi and Regeneron’s atopic dermatitis drug, Dupixent, can make a bid for asthma sales, the companies are churning out data in a variety of other conditions in hopes of boosting the product even more. The latest? Positive numbers from two phase 3 trials…...

Source: FierceBiotech Alexion’s rebuilding plan has continued with another bolt-on acquisition, this time a $400 million upfront deal for rare disease specialist Syntimmune. The takeover gives Alexion control of SYNT001—a neonatal Fc receptor (FcRn) inhibitor in phase 1b/2a trials for patients with warm autoimmune hemolytic anemia (WAIHA) and pemphigus vulgaris (PV)…...

Source: FierceHealthcare The Department of Justice has given the green light to insurance giant Cigna Corp.'s planned $67 billion acquisition of pharmacy benefit manager Express Scripts. The move terminates the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, one of the conditions necessary to close the deal, officials said in…...